

Extracorporeal CO₂ removal enhanced by lactic acid infusion in spontaneously breathing conscious sheep

Authors:

Vittorio Scaravilli, Stefan Kreyer, Slava Belenkiy, Katharina Linden, Alberto Zanella, Yansong Li, Michael Dubick, Leopoldo C. Cancio, Antonio Pesenti, Andriy I. Batchinsky

SUPPLEMENTAL DIGITAL CONTENT

The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

Additional Methods

Instrumentation

The animals were endotracheally intubated after an intramuscular injection (i.m.) of glycopyrrolate (100 µg/kg) and tiletamine-zolazepam (6 mg/kg). During surgical preparation, general inhalation anesthesia was maintained with isoflurane (MAC 1.0-1.5) and analgesia was obtained by administering an intravenous (i.v.) bolus of Fentanyl 5 µg/kg, followed by continuous infusion at 5 µg/kg/hr. A Foley catheter was inserted to monitor urinary output. Surgical preparations included the following. The left carotid artery was percutaneously cannulated with a 16G pediatric central venous catheter (Arrow International, Reading, PA) for pressure monitoring and blood gas analyses. An 8.5-F sheath introducer (Arrow International, Reading, PA) was placed into the left external jugular vein, for i.v. administration of medications and to facilitate the placement of a Swan-Ganz catheter (Edwards Lifescience, Irvine, CA) which was used to monitor central venous, pulmonary artery and wedge pressures, cardiac output, and core temperature and for sampling of mixed venous blood. Surgical tracheostomy was performed using a cuffed adult tracheostomy tube (10mm, Shiley, Covidien, Boulder, CO). Antibiotic prophylaxis (ceftriaxone 2 g) i.v. was administered. A dual-lumen catheter (Hemolung, Alung, Alung Technologies, Pittsburgh, PA) 15.5-F was percutaneously introduced in the right external jugular vein after i.v. bolus of unfractionated heparin (UFH, 100 UI/kg). Subsequently heparin was infused continuously to maintain activated clotting time (ACT) at approximately 150% of the baseline values. ACT was measured with Hemochron Signature Elite (ITC, Edison, NJ, USA).




Figure S1. Experimental design. LA, lactic acid.

Each of the animals underwent 2 repetitions of the experimental sequences consisting of an ALCO₂R phase and a standard ECCO₂R phase. ALCO₂R and ECCO₂R phases were always alternated and lasted 12 hours each. To counterbalance any order effect of the experimental design, 3 animals started the experiment with a standard ECCO₂R phase (i.e. experimental sequence A), while 3 started with an ALCO₂R phase (i.e. experimental sequence B).

Equations A (Ventilatory Function calculation):

Knowing membrane lung (ML) CO₂ removal (VCO₂ML) at body temperature pressure saturated (BTPS) conditions,

Alveolar ventilation (AV) as well as physiologic dead space (V_d) were calculated using standard equation,⁷ as follows:

$$\text{Expired CO}_2 \text{ fraction} = FeCO_2 = \frac{VCO_2NL (L/min)}{MV(L/min)}$$

$$\text{Partial Pressure of CO}_2 \text{ in expired gases} = PeCO_2(mmHg) = FeCO_2 \times 760 mmHg$$

$$\text{Dead Space Fraction} = \frac{Vd}{Vt} = \frac{(PaCO_2(mmHg) - PeCO_2(mmHg))}{PaCO_2(mmHg)}$$

$$\text{Physiologic Dead Space (mL)} = \frac{(PaCO_2(mmHg) - PeCO_2(mmHg))}{PaCO_2(mmHg)} \times TV (mL)$$

$$\text{Alveolar Ventilation} = AV(L/min) = MV(L/min) - MV(L/min) \times \frac{Vd}{Vt}$$

Once collected arterial and mixed venous arterial blood gas analyses as well as measured cardiac output (CO) by thermodilution technique, venous admixture (Qs/Qt) was calculated using standard equation,⁷ as follows:

$$\text{Venous Admixture} = \frac{Qs}{Qt} = \frac{Cc (mL/dL) - Cv (mL/dL)}{Cc (mL/dL) - Ca (mL/dL)}$$

Where Ca is the arterial content of oxygen calculated as:

$$Ca (mL/dL) = \left(0.0031 \left(\frac{mL/dL}{mmHg} \right) \cdot P_{art}O_2(mmHg) + 1.39 (mL/gr) \cdot Hb (gr/dL) \cdot Sat_{art}O_2 (\%) \right);$$

Cv is the mixed venous content of oxygen, calculated as follows:

$$Cv (mL/dL) = \left(0.0031 \left(\frac{mL/dL}{mmHg} \right) \cdot P_{ven}O_2(mmHg) + 1.39 (mL/gr) \cdot Hb (gr/dL) \cdot Sat_{ven}O_2 (\%) \right);$$

and Cc is the pulmonary capillary content of oxygen, calculated as follows:

$$Cc (mL/dL) = \left(0.0031 \left(\frac{mL/dL}{mmHg} \right) \cdot P_{ALV}O_2(mmHg) + 1.39 (mL/gr) \cdot Hb(gr/dL) \right).$$

Where P_{ALV}O₂ is the alveolar partial pressure of oxygen, calculated as follows:

$$P_{ALV}O_2 = (713 \times FiO_2) - \frac{PaCO_2(mmHg)}{RQ}$$

Where 713 is the atmospheric pressure, 47 is water vapor pressure, PaCO₂ is the partial pressure of CO₂ in arterial blood

and RQ is the respiratory quotient, calculated as the ratio of carbon dioxide production (VCO₂tot) and oxygen consumption (VO₂tot).

Equations B (Membrane Lung CO₂ removal efficiency calculation):

Once measured membrane lung CO₂ removal (VCO₂ML, mL/min), extracorporeal blood flow (BF, L/min) and circuit inlet total content of CO₂ (Inlet ctCO₂, mL/dL), membrane lung CO₂ removal efficiency was computed as previously described,⁸ as follows:

$$\text{MLCO}_2 \text{ Efficiency (\%)} = \frac{\text{VCO}_2\text{ML (mL/min)}}{\text{Inlet ctCO}_2(\text{mL/L}) \times \text{BF (L/min)}}$$

Where Inlet ctCO₂ was total blood CO₂ content at the inlet of the ML and was calculated according to a simplified and standardized Henderson-Hasselbach equation formula, which is commonly used and approved for blood gas analyzers calculations,⁹ as the sum of the bicarbonate ions concentration and dissolved CO₂ obtained by the pCO₂ and CO₂ solubility coefficient (αCO₂ = 0.03 mMol × L⁻¹ × mmHg⁻¹). Therefore, total CO₂ content is calculated as follows:

$$\text{Inlet ctCO}_2 = \text{Inlet chCO}_3^- + (\alpha\text{CO}_2 \times \text{Inlet pCO}_2)$$

Equations C (Oxygen Delivery and Consumption calculation):

ML Oxygen delivery (VO₂ML) at BTPS conditions was calculated as follows:

$$\begin{aligned} \text{VO}_2\text{ML (mL/min)} &= [(0.0031 \cdot P_{\text{Outlet } O_2}(\text{mmHg}) + 1.39 \cdot \text{Hb(g/dL)} \cdot \text{Sat}_{\text{Outlet } O_2}(\%)) \\ &- (0.0031 \cdot P_{\text{Inlet } O_2}(\text{mmHg}) + 1.39 \cdot \text{Hb(g/dL)} \cdot \text{Sat}_{\text{Inlet } O_2}(\%))] \times \text{BF (L/min)} \times 10 \end{aligned}$$

Natural lung Oxygen delivery (VO₂NL) at BTPS conditions was calculated as follows:

$$\begin{aligned} \text{VO}_2\text{NL (mL/min)} &= [(0.0031 \cdot P_{\text{Art } O_2}(\text{mmHg}) + 1.39 \cdot \text{Hb(g/dL)} \cdot \text{Sat}_{\text{Art } O_2}(\%)) \\ &- (0.0031 \cdot P_{\text{MixedVenous } O_2}(\text{mmHg}) + 1.39 \cdot \text{Hb(g/dL)} \cdot \text{Sat}_{\text{MixedVenous } O_2}(\%))] \times \text{CO (L/min)} \times 10 \end{aligned}$$

Accordingly, oxygen consumption (VO₂tot) at BTPS conditions was calculated as:

$$\text{VO}_2\text{tot (mL/min)} = \text{VO}_2\text{ML (mL/min)} + \text{VO}_2\text{NL (mL/min)}$$

Equations D (Energetic Expenditure calculation):

Knowing carbon dioxide production (VCO₂tot) and oxygen consumption (VO₂tot), energetic expenditure (EE) was calculated using Weir Equation, as previously described,¹⁰ as follows:

$$\text{Energy Expenditure (kCal/hr)} = \text{EE} = (3.94 \times \text{VO}_2\text{tot (mL/min)} + 1.11 \times \text{VCO}_2\text{tot (mL/min)}) \times 0.06$$

Post-mortem histological evaluation

Lung, heart, liver and renal tissue samples were collected for histological evaluation post-mortem. The tissue samples were fixed in neutral-buffered 10% formalin for 24 hrs, trimmed, embedded in paraffin, sectioned at 4 μ m, and stained with hematoxylin and eosin (H&E). Histological images were recorded with 10, 20, and 40 \times objective under a light microscope (AX80; Olympus, Center Valley, Pa). Histological evaluation of injury was performed by a single pathologist blinded to the identity of the animal represented on the slide, as previously documented.¹

Five parameters (alveolar fibrin edema, alveolar hemorrhage, septal thickening, intra-alveolar inflammation and vasculitis), four parameters (edema, degeneration, inflammatory cell infiltration, congestion), and four parameters (vascular congestion/thrombosis, cellular death, cellular degeneration, inflammation) were as criteria for pulmonary, cardiac, and hepatic as well as kidney injury respectively. Tissue injury was assessed on each H&E stained slide for: 1) severity of injury (0: absent; 1, 2, 3, and 4 for more severe changes), and 2) extent of injury.

Oxidative Stress and Inflammation Analysis

Lung, heart and liver tissues from the sheep were homogenized in 50 mM potassium phosphate buffer, pH 7.4.

Malondialdehyde concentrations in these tissues, as an index of lipid peroxidation, were determined as thiobarbituric acid reactive substances (TBARs) in the butanol phase using 1,1,3,3-tetraethoxypropane as standard, as described by the method of Naito, et al.² Ferric reducing ability of lung, heart and liver, as an index of their overall antioxidant status, was determined spectrophotometrically by the method of Benzie and Strain.³ Reduced glutathione (GSH) were determined enzymatically as described by Anderson.⁴ Myeloperoxidase activity in lung was determined by a modification of the method of Trush, et al.⁵ Briefly, tissues were homogenized in 50 mM potassium phosphate buffer pH 6.0 containing 0.5% hexadecyltrimethylammonium bromide. The homogenates then underwent 3 freeze-thaw cycles and sonification, followed by incubation at 60 $^{\circ}$ C in a water bath for 2 hr to extract myeloperoxidase and reduce interfering substances. Samples were then centrifuged at 10,000 x g for 30 min at 4 $^{\circ}$ C. Myeloperoxidase activity was determined in the resultant supernatant using o-dianisidine as substrate. Total nitric oxide concentrations in the tissues were determined by a commercial kit (Stressgen, Victoria, BC, Canada). Tissue levels of IL-1 β and IL-8 were determined by ELISA using commercial kits (R&D Systems, Minneapolis, MN). Tissue protein concentrations were determined with a commercial kit (Pierce, Rockford, IL).

Healthy controls were obtained from a previous study performed in our laboratory.¹¹ In that study, 5 healthy neutered male sheep (*Ovis aeries*, Rambouillet X) with mean weight 30 kg, underwent similar instrumentation as in our study (i.e. general

anesthesia, tracheostomy, central venous cannulation, arterial cannulation, pulmonary artery cannulation). After a time period of 52 hours (i.e. as in our study), sham-animals were euthanatized with an i.v. injection of 20 mL of Fatal Plus (Vortech Pharmaceuticals, Dearborn, MI) and lung, heart, liver and renal tissue were collected for tissue inflammatory responses, concentration of selected indices of oxidative stress and biochemical markers of injury. Measurement of thiobarbituric acid reactive substances (TBARs), interleukin-1 β (IL-1 β), and nitric oxide concentration, determined reduced glutathione (GSH), ferric reducing ability in the homogenate of lung, heart and liver tissue were performed with the aforementioned techniques in the same laboratory. Myeloperoxidase activity was measured in lung homogenate. Interleukin-8 (IL-8) was measured only in homogenate of lung and liver.

Additional Results

Fig. E1




Figure S2. Time dependent variation of lactate concentration during ALCO₂R. *) $p < 0.001$ versus all the other time points.

Table S1. Hemodynamics parameters during ECCO₂R and ALCO₂R.

	ECCO₂R	ALCO₂R	<i>P</i> value
T [°] c	39.7 ± 0.5	39.8 ± 0.6	< 0.001
HR (bpm)	118 ± 21	124 ± 22	0.006
MAP (mmHg)	98 ± 9	99 ± 10	0.206
CVP(mmHg)	8 ± 3	7 ± 3	0.065
PAOP (mmHg)	15 ± 4	15 ± 4	0.096
CO (L/min)	7.2 ± 1.5	7.6 ± 1.5	0.023
SvO ₂ (%)	72.9 ± 5.1	71.7 ± 5.9	0.167
Hct (%)	26.7 ± 4.7	26.3 ± 4.5	0.067


Core temperature (T[°]c), Heart Rate (HR), Mean Arterial Pressure (MAP), Central Venous Pressure (CVP), Pulmonary Artery Occlusion Pressure (PAOP), Cardiac Output (CO), Mixed Venous Saturation (SvO₂), Hematocrit (Hct).

Table S2. Blood chemistry during different experimental phases.

	BL	EC	ECCO₂R	ALCO₂R
PFHb (mg/dL)	9.6 (4.4 - 9.8)	3.4 (3.1 - 4.8)	7.0 (4.3 - 8.2)	6.7 (4.0 - 8.4)
WBC (K/μL)	3.8 (3.3 - 4.2)	6.2 (4.3 - 9.2)*	8.4 (5.2 - 9.2)*	7.7 (6.0 - 9.1)*
NEU (K/μL)	1.0 (0.5 - 2.2)	4.0 (2.5 - 7.7)*	5.4 (2.7 - 6.0)*	4.5 (3.1 - 6.0)*
LYM (K/μL)	2.6 (1.2 - 3.1)	1.1 (0.6 - 2.9)	2.1 (1.7 - 3.1)	2.6 (1.7 - 3.0)
RBC (M/μL)	8.6 (7.8 - 8.9)	7.7 (6.2 - 8.1)*	7.3 (6.9 - 8.0)*	7.2 (6.0 - 7.9)*
Hct (%)	29.6 (27.5 - 32.2)	26.9 (22.1 - 30.6)*	26.9 (23.4 - 30.2)*	26.7 (22.1 - 28.7)*
PLT (K/μL)	478 (163 - 694)	317 (124 - 398)*	182 (139 - 292)*	167 (116 - 257)*
PT (sec)	11.8 (11.4 - 14.0)	13.5 (12.6 - 13.9)	12.0 (11.7 - 12.7)	12.5 (11.8 - 13.6)
PTT (sec)	28.0 (23.7 - 45.7)	86.7 (70.4 - 103.6)*	64.6 (46.7 - 81.2)*	66.1 (62.5 - 105.1)*
FBG (mg/dL)	257 (134 - 378)	141 (112 - 211)	303 (223 - 510)	492 (227 - 567)
DD (mg/L)	0.27 (0.17 - 0.51)	0.23 (0.17 - 0.32)	0.19 (0.17 - 0.29)	0.21 (0.18 - 0.27)
CREA (mg/dL)	0.70 (0.65 - 0.85)	0.80 (0.70 - 0.95)	0.70 (0.60 - 0.80)	0.75 (0.63 - 0.90)
BIL (mg/dL)	0.02 (0.01 - 0.06)	0.09 (0.02 - 0.20)§	0.00 (0.00 - 0.00)	0.00 (0.00 - 0.00)†
ALT (IU/L)	25 (20 - 27)‡,§	24 (24 - 29)‡,§	34 (26 - 38)*,†	30 (26 - 38)*,†
AST (IU/L)	87 (72 - 111)	125 (108 - 156)*	140 (113 - 179)*	134 (118 - 166)*
AMYL (IU/L)	17 (9 - 21)	20 (14 - 23)	10 (5 - 17)	9 (7 - 13)
URCA (mg/dL)	0.1 (0.1 - 0.2)	0.1 (0.1 - 0.2)	0.1 (0.1 - 0.2)	0.1 (0.1 - 0.2)
MYOG (ng/mL)	1.0 (0.6 - 3.0)	1.0 (1.0 - 3.0)	1.0 (1.0 - 2.0)	1.5 (1.0 - 2.8)
GLU (mg/dL)	56 (47 - 85)§	73 (57 - 90)*	67 (61 - 69)§	75 (73 - 78)*, ‡

Baseline before instrumentation (BL), after 6 hours of extracorporeal circulation (EC), after 12 hours of ECCO₂R (ECCO₂R), after 12 hours of ALCO₂R (ALCO₂R). Data is describe as median and interquartile range. Plasma Free Hemoglobin (PFHb), White Blood Cells (WBC), Neutrophils (NEU), Lymphocytes (LYM), Red Blood Cells (RBC), Hematocrit (Hct), Platelets (PLT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Fibrinogen (FBG), D-Dimers (DD), Creatinine (CREA), Total Bilirubin (BIL), Alanine Transaminase (ALT), Aspartate Transaminase (AST), Amylase (AMYL), Myoglobin (MYOG), Uric Acid (URCA). Tukey's post-hoc analysis: *) p < 0.05, vs. BL, †) p < 0.05, vs. EC, ‡) p < 0.05, vs. ECCO₂R, §) p < 0.05, vs. ALCO₂R.

Figure S3. Post-mortem histological evaluation.



Formalin-fixed tissues were embedded in paraffin, sectioned, and stained with hematoxylin-eosin. Histological images were obtained under a light microscope. A, Lung. Representative micrograph shows normal lung structure characterized by thin alveolar septa with occasional intra-alveolar macrophages and very few neutrophils, (magnification x200). B, Heart. Representative micrograph demonstrates normal myocardial structures, (magnification x400). C, Liver. Representative micrograph displays normal hepatic lobule, central vein, and portal triads without pathological alteration. (magnification x200). D, Kidney. Representative micrograph exhibits intact renal corpuscles and tubules without obvious vascular congestion, inflammation, and cellular death/degeneration (magnification x100).

Table S4. Histological evaluation of end organs.

Tissue	Animal														
Lung		Alveolar Fibrin Edema		Extent	Alveolar Hemorrhage		Extent	Septal Thickening		Extent	Alveolar Inflammation		Extent	Vasculitis	Extent
	1		0	0%		0	0%		0	0%		0	0%	0	0%
	2		0	0%		0	0%		0	0%		0	0%	0	0%
	3		0	0%		0	0%		0	0%		0	0%	0	0%
	4		0	0%		0	0%		2	25-50%		2	25-50%	1	<25%
	5		0	0%		0	0%		0	0%		0	0%	0	0%
	6		0	0%		0	0%		0	0%		0	0%	0	0%
	Heart		Edema		Extent	Degeneration		Extent	Inflammatory cell infiltration		Extent	Congestion		Extent	
1			0	0%		0	0%		0	0%		0	0%		
2			1	<25%		1	<25%		0	0%		0	0%		
3			1	<25%		1	<25%		0	0%		0	0%		
4			0	0%		0	0%		0	0%		0	0%		
5			0	0%		0	0%		0	0%		0	0%		
6			1	<25%		1	<25%		0	0%		0	0%		
Liver			Vascular Congestion		Extent	Cellular Death		Extent	Cellular Degeneration		Extent	Inflammation		Extent	
	1		0	0%		0	0%		0	0%		0	0%		
	2		0	0%		0	0%		1	<25%		1	<25%		
	3		0	0%		0	0%		1	<25%		1	<25%		
	4		0	0%		0	0%		0	0%		0	0%		
	5		0	0%		0	0%		0	0%		0	0%		
	6		0	0%		0	0%		0	0%		0	0%		
	Kidney		Vascular Congestion		Extent	Cellular Death		Extent	Cellular Degeneration		Extent	Inflammation		Extent	
1			0	0%		0	0%		0	0%		0	0%		
2			0	0%		0	0%		0	0%		0	0%		
3			0	0%		0	0%		0	0%		0	0%		
4			1	25%		0	0%		0	0%		1	<25%		
5			0	0%		0	0%		0	0%		0	0%		
6			0	0%		0	0%		0	0%		0	0%		

Tissue injury was assessed on each hematoxylin and eosin stained slide for: 1) severity of injury (0: absent; 1, 2, 3, and 4 for more severe changes), and 2) extent of injury.

Table S4. Indices of Oxidative Stress and Inflammation.

		ALCO₂R	Control	P value
TBARs (nmol/mg protein)	Lung	1.69 ± 1.98	2.24 ± 0.52	0.567
	Heart	1.58 ± 0.29	3.90 ± 1.20	0.002
	Liver	6.84 ± 1.98	9.14 ± 0.64	0.037
Total Antioxidant (μmol/mg protein)	Lung	5.90 ± 0.73	4.50 ± 0.40	0.005
	Heart	4.60 ± 0.49	2.60 ± 2.00	0.060
	Liver	9.70 ± 1.22	8.60 ± 0.80	0.131
GSH (μmol/mg protein)	Lung	0.66 ± 0.20	0.35 ± 0.12	0.015
	Heart	1.43 ± 0.15	1.64 ± 0.42	0.323
	Liver	3.72 ± 1.74	2.80 ± 0.80	0.315
Nitric Oxide (nmol/mg protein)	Lung	6.50 ± 1.96	4.10 ± 2.00	0.090
	Heart	15.90 ± 4.41	11.20 ± 1.40	0.051
	Liver	24.80 ± 6.61	22.30 ± 2.00	0.443
IL-1β (pg/mg protein)	Lung	61.30 ± 15.92	51.70 ± 7.60	0.259
	Heart	72.70 ± 34.29	87.50 ± 36.60	0.530
	Liver	58.30 ± 15.92	32.90 ± 2.80	0.007
IL-8 (pg/mg protein)	Lung	56.70 ± 11.76	28.80 ± 9.60	0.003
	Heart	21.50 ± 9.06	---	---
	Liver	32.80 ± 2.45	27.80 ± 3.80	0.281
Myeloperoxidase (U/mg protein)	Lung	6.80 ± 4.90	8.80 ± 5.20	0.786

Thiobarbituric acid reactive substances (TBARs), reduced glutathione (GSH), interleukin-1β (IL-1β), interleukin-8 (IL-8).

*) p < 0.05 versus control sheep.

Additional References

1. Dalle Lucca JJ, Li Y, Simovic MO, Slack JL, Cap A, Falabella MJ, Dubick M, Lebeda F, Tsokos GC: Decay-accelerating factor limits hemorrhage-instigated tissue injury and improves resuscitation clinical parameters. *J Surg Res* 2013; 179:153–167
2. Naito C, Kawamura M, Yamamoto Y: Lipid peroxides as the initiating factor of atherosclerosis. *Ann N Y Acad Sci* 1993; 676:27–45
3. Benzie IF, Strain JJ: The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. *Anal Biochem* 1996; 239:70–6
4. Anderson M: Glutathione and glutathione disulfide in biological samples. *Methods Enzymol* 1985; 113:548–555
5. Trush MA, Egner PA, Kensler TW: Myeloperoxidase as a biomarker of skin irritation and inflammation. *Food Chem Toxicol* 1994; 32:143–147
6. Siobal MS, Ong H, Valdes J, Tang J: Calculation of physiologic dead space: comparison of ventilator volumetric capnography to measurements by metabolic analyzer and volumetric CO₂ monitor. *Respir Care* 2013; 58:1143–51
7. Riley RI, Cournand A: Ideal alveolar air and the analysis of ventilation-perfusion relationships in the lungs. *J Appl Physiol* 1949; 1:825–47
8. Scaravilli V, Kreyer S, Linden K, Belenkiy S, Jordan B, Pesenti A, Zanella A, Chung K, Cannon J, Cancio LC, Batchinsky AI: Modular extracorporeal life support: effects of ultrafiltrate recirculation on the performance of an extracorporeal carbon dioxide removal device. *ASAIO J* 2014; 60:335–41
9. (CLSI) C and LS. Blood Gas and pH Analysis and Related Measurements. In: Blood Gas and pH Analysis and Related Measurements. Vol 21. Wayne, PA 19087; 2009:3.

10. Touho H, Karasawa J, Shishido H, Yamada K, Shibamoto, K: Direct calorimetry using Swan-Ganz catheter for evaluation of general metabolic expenditure in acute cerebrovascular disease--comparison between direct Fick method and indirect calorimetry technique. *Neurol Med Chir (Tokyo)* 1991; 31:691–4
11. Park MS, Cancio LC, Jordan BS, et al.: Assessment of oxidative stress in lungs from sheep after inhalation of wood smoke. *Toxicology* 2004; 195:97–112